Spectral AI Appoints Darcy Bajko as Chief Commercial Officer to Lead DeepView System Global Sales Launch
MDAI sits 47% above its 52-week low of $1.18 on light trading volume (0.2× avg).
Summary
Spectral AI appointed Darcy Bajko as Chief Commercial Officer, a critical step to lead the global sales launch of its recently FDA-cleared DeepView System and drive revenue growth.
Key Events · Executive and Board Changes · MDAI
-
New Chief Commercial Officer Appointed
Darcy Bajko has been appointed as Chief Commercial Officer, effective July 31, 2026.
-
Strategic Commercialization Focus
Ms. Bajko will lead the global sales launch of the FDA-cleared DeepView® System for burn indication, a critical step following its May 2026 regulatory approval. Her background includes successfully launching multiple FDA-cleared augmented reality imaging platforms and building commercial organizations.
-
Executive Compensation Package
Her compensation includes an annual base salary of $315,000, an annual target bonus of up to 30% of her base, and a grant of 150,000 stock options vesting over three years.
Analysis · MDAI · Industrial Applications And Services
This appointment is a pivotal move for Spectral AI, signaling a strong pivot towards commercialization after receiving FDA De Novo Classification for its DeepView System in May. Given the company's reported decline in Q1 2026 revenue and increased cash burn, bringing in an experienced Chief Commercial Officer like Ms. Bajko, with a proven track record in launching FDA-cleared medical devices and driving revenue, is crucial for converting regulatory success into financial performance and extending the company's runway.
At the time of this filing, MDAI was trading at $1.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $55.1M. The 52-week trading range was $1.18 to $3.21. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.